A Phase 3 interventional study of Capecitabine and Capecitabine in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 190 sites in 23 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-14.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.
Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 15th largest by enrollment, is one of 3 that started in 2010, is one of 23 in phase 3, and was the 6th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pertuzumab is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 63 · Phase 3 23 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 104 interventional studies. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 104 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 37th largest by enrollment of the 170 interventional ones that give a count, is one of 15 that started in 2010, is one of 61 in phase 3, and was the 63rd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
10 of the studies testing pertuzumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07187752Shandong Cancer Hospital and InstituteIdentification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes | 2026-12-31 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies testing pertuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Capecitabine · Drug: Trastuzumab
Drug: Capecitabine · Drug: Pertuzumab · Drug: Trastuzumab
1000 mg/m2 po twice daily for 14 days every 3 weeks
Also known as: Xeloda
1250 mg/m2 po twice daily for 14 days every 3 weeks
Also known as: Xeloda
840 mg iv loading, then 420 mg iv every 3 weeks
Also known as: Perjeta
8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
Also known as: Herceptin
Progression Free Survival (Independent Assessment)
Progression Free Survival (PFS) was defined as the time from randomization to first documented disease progression (PD), as determined by an Independent Review Facility (IRF) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. IRF review of tumor assessment ceased after the primary PFS analysis. The primary endpoint was analyzed after approximately 337 IRF-assessed PFS events were observed.
Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Overall Survival (OS)
Overall Survival (OS) was defined as the time from the date of randomization to the date of death from any cause. The results of the final OS analysis are presented here. Participants who were alive or lost to follow-up at the time of the analysis were censored at the last known alive date. Participants with no postbaseline information were censored at the time of randomization plus 1 day. Prior to the final data analysis cut-off, it was ensured that all participants who were in survival follow-up had been contacted as recently as possible within the last 3 months to confirm current survival status.
Time frame: From randomization until death from any cause (up to 7.5 years).
Overall Survival (OS) Rate Based on a 2-year Truncated Analysis
The Overall Survival (OS) 2-year truncated analysis is the Kaplan-Meier estimate of the percentage of participants who were surviving at 2 years. OS is defined as the time from the date of randomization to the date of death from any cause, with censoring of all events and follow-up beyond the end of the second year.
Time frame: From randomization until death from any cause (up to 2 years)
Investigator Assessment Progression-Free Survival (PFS)
Investigator Assessment Progression-Free Survival (PFS) was defined as the time from randomization to the first documented progressive disease, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0, or death from any cause, whichever occurred first. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 7.5 years).
Time to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment
Time to Progression (TTP) was defined as time between randomization and the first occurrence of progressive disease (PD), based on IRF assessment.
Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Time to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment
Time to Treatment Failure (TTF) was defined as time between randomization and date of disease progression based on independent review, death, or withdrawal of treatment due to adverse events, withdrawn informed consent, refusal of treatment/failure to cooperate, or failure to return, whichever occurred first.
Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Overall Objective Response Rate (ORR)
Overall Objective Response Rate is based upon investigator and IRF assessments. Objective Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among those who had measurable disease at baseline. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Clinical Benefit Rate (CBR)
Clinical Benefit Rate is based upon Independent Review Facility (IRF) assessments; defined as the percentage of participants a complete response (CR), partial response (PR), or stable disease for at least 8 cycles or 6 months.
Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Duration of Objective Response
Duration of Objective Response was defined for the subpopulation of responders as time from first Independent Review Facility (IRF)-assessed complete response (CR) or partial response (PR) to subsequent first documented, IRF-confirmed evidence of disease progression. Only participants with an objective response were included in the analysis of duration of objective response.
Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
452 participants were randomized to one of two treatment arms: trastuzumab and capecitabine (Arm A, 224 participants) or pertuzumab with trastuzumab and capecitabine (Arm B, 228 participants). Of participants randomized to Arm A: trastuzumab and capecitabine, 6 participants did not receive study treatment.
| Milestone | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Started | 224 | 228 |
| Completed | 52 | 65 |
| Not completed | 172 | 163 |
| Withdrew: Death | 136 | 134 |
| Withdrew: Withdrew consent or lost to follow-up | 36 | 29 |
Progression Free Survival (PFS) was defined as the time from randomization to first documented disease progression (PD), as determined by an Independent Review Facility (IRF) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. IRF review of tumor assessment ceased after the primary PFS analysis. The primary endpoint was analyzed after approximately 337 IRF-assessed PFS events were observed.
| months | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Progression Free Survival (Independent Assessment) | 9.0 (8 to 10) | 11.1 (9 to 13) |
Overall Survival (OS) was defined as the time from the date of randomization to the date of death from any cause. The results of the final OS analysis are presented here. Participants who were alive or lost to follow-up at the time of the analysis were censored at the last known alive date. Participants with no postbaseline information were censored at the time of randomization plus 1 day. Prior to the final data analysis cut-off, it was ensured that all participants who were in survival follow-up had been contacted as recently as possible within the last 3 months to confirm current survival status.
| Months | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Overall Survival (OS) | 28.1 (22 to 35) | 37.2 (33 to 42) |
The Overall Survival (OS) 2-year truncated analysis is the Kaplan-Meier estimate of the percentage of participants who were surviving at 2 years. OS is defined as the time from the date of randomization to the date of death from any cause, with censoring of all events and follow-up beyond the end of the second year.
| Percentage of participants | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Overall Survival (OS) Rate Based on a 2-year Truncated Analysis | 55.0 (48.07 to 61.85) | 74.9 (69.05 to 80.68) |
Investigator Assessment Progression-Free Survival (PFS) was defined as the time from randomization to the first documented progressive disease, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0, or death from any cause, whichever occurred first. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
| Months | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Investigator Assessment Progression-Free Survival (PFS) | 9.0 (8 to 12) | 11.8 (9 to 14) |
Time to Progression (TTP) was defined as time between randomization and the first occurrence of progressive disease (PD), based on IRF assessment.
| Weeks | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Time to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment | 39.0 (35 to 44) | 50.6 (39 to 62) |
Time to Treatment Failure (TTF) was defined as time between randomization and date of disease progression based on independent review, death, or withdrawal of treatment due to adverse events, withdrawn informed consent, refusal of treatment/failure to cooperate, or failure to return, whichever occurred first.
| Weeks | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Time to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment | 39.0 (34 to 44) | 50.9 (39 to 62) |
Overall Objective Response Rate is based upon investigator and IRF assessments. Objective Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among those who had measurable disease at baseline. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
| Percentage of participants | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Complete Response (CR) - IRF Assessment | 0 | 1.8 |
| Partial Response (PR) - IRF assessment | 32.9 | 38.7 |
| Complete Response (CR) - Investigator Assessed | 1.2 | 6.7 |
| Partial Response (PR) - Investigator Assessed | 36.0 | 38.0 |
Clinical Benefit Rate is based upon Independent Review Facility (IRF) assessments; defined as the percentage of participants a complete response (CR), partial response (PR), or stable disease for at least 8 cycles or 6 months.
| Percentage of participants | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Clinical Benefit Rate (CBR) | 54.0 (47.3 to 60.7) | 63.6 (57.0 to 69.8) |
Duration of Objective Response was defined for the subpopulation of responders as time from first Independent Review Facility (IRF)-assessed complete response (CR) or partial response (PR) to subsequent first documented, IRF-confirmed evidence of disease progression. Only participants with an objective response were included in the analysis of duration of objective response.
| Weeks | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Duration of Objective Response | 30.0 (21 to 42) | 51.6 (42 to 57) |
Collected over Adverse events were recorded and reported during the study and up to two years after the last dose of the study drug was received.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A: Capecitabine + Trastuzumab | 136/218 (62.4%) | 53/218 (24.3%) | 209/218 (95.9%) |
| B: Capecitabine + Trastuzumab + Pertuzumab | 134/228 (58.8%) | 58/228 (25.4%) | 216/228 (94.7%) |
| Event | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Left Ventricular DysfunctionCardiac disorders | 4/218 | 13/228 |
| DiarrhoeaGastrointestinal disorders | 6/218 | 8/228 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 4/218 | 3/228 |
| NauseaGastrointestinal disorders | 2/218 | 1/228 |
| VomitingGastrointestinal disorders | 2/218 | 1/228 |
| Femur FractureInjury, poisoning and procedural complications | 2/218 | 2/228 |
| SepsisInfections and infestations | 2/218 | 0/228 |
| SyncopeNervous system disorders | 2/218 | 1/228 |
| General Physical Health DeteriorationGeneral disorders | 2/218 | 2/228 |
| PyrexiaGeneral disorders | 2/218 | 2/228 |
| Event | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab |
|---|---|---|
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 159/218 | 129/228 |
| DiarrhoeaGastrointestinal disorders | 128/218 | 157/228 |
| NauseaGastrointestinal disorders | 97/218 | 88/228 |
| AstheniaGeneral disorders | 51/218 | 47/228 |
| VomitingGastrointestinal disorders | 45/218 | 37/228 |
| FatigueGeneral disorders | 39/218 | 44/228 |
| StomatitisGastrointestinal disorders | 32/218 | 41/228 |
| HeadacheNervous system disorders | 39/218 | 40/228 |
| NeutropeniaBlood and lymphatic system disorders | 38/218 | 29/228 |
| Decreased AppetiteMetabolism and nutrition disorders | 28/218 | 36/228 |
This is the safety population, which includes all participants who received any amount of study drug; 6 participants randomized to the Capecitabine + Trastuzumab arm withdrew before receiving any study treatment.
| Age, Continuous(years) | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab | Total |
|---|---|---|---|
| Mean | 55.1 ± 10.10 | 53.0 ± 11.21 | 54.0 ± 10.72 |
| Sex: Female, Male(Participants) | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab | Total |
|---|---|---|---|
| Female | 218 | 228 | 446 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | A: Capecitabine + Trastuzumab | B: Capecitabine + Trastuzumab + Pertuzumab | Total |
|---|---|---|---|
| Russian Federation | 8 | 3 | 11 |
| Argentina | 3 | 4 | 7 |
| Romania | 6 | 8 | 14 |
| Hungary | 13 | 29 | 42 |
| Hong Kong | 5 | 11 | 16 |
| United Kingdom | 18 | 17 | 35 |
| Thailand | 0 | 5 | 5 |
| Spain | 39 | 31 | 70 |
| Canada | 3 | 6 | 9 |
| Czech Republic | 12 | 10 | 22 |
| Austria | 2 | 3 | 5 |
| Netherlands | 0 | 2 | 2 |
| Belgium | 12 | 11 | 23 |
| Poland | 6 | 6 | 12 |
| Brazil | 7 | 6 | 13 |
| Korea, Republic of | 14 | 24 | 38 |
| Italy | 16 | 18 | 34 |
| Mexico | 1 | 0 | 1 |
| France | 19 | 12 | 31 |
| Peru | 7 | 8 | 15 |
| Germany | 23 | 11 | 34 |
| Croatia | 4 | 3 | 7 |
Showing the first 100 of 190 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Jan 2010 to primary completion in May 2015, 64 months.
Results were first posted in Oct 2016, 1 year 4 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 64 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab